Newly created role of Chief Patient Officer reinforces Compass’ vision of working to achieve broad and equitable access to COMP360, if approved “Steve has spent the past four years working to deeply ...

New executive appointment made ahead of pivotal study results, potential regulatory approval and subsequent commercialization of investigational COMP360 psilocybin treatment Latest of several key ...

With an estimated 51.5 million U.S. adults suffering from mental illness and the psychedelic drug market projected to grow at ...

Q2 2025 Management View Kabir Kumar Nath, CEO, announced the appointment of Justin Gover, former CEO of GW Pharmaceuticals, to the Board of Directors, highlighting his experience with "Epidiolex, the ...

COMPASS Pathways focuses on developing COMP360 psilocybin for treatment-resistant depression, facing significant challenges due to its Schedule I status. Key risks include market acceptance, ...

LONDON, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental ...

Encouraging trial data is instilling both confidence and capital back into the psychedelic drug market, with estimates ...

We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. COMPASS Pathways Plc is one of them. COMPASS Pathways Plc (NASDAQ:CMPS), a biotechnology company specializing in ...

LONDON & NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...

LONDON, June 26, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS) (“Compass”), a biotechnology company dedicated to accelerating access to evidence-based innovation in mental health, today ...